Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biosimilar Trends Report

- PMLiVE

Industry aghast as EU Parliament backs biosimilar rule change

The change could come into effect in 2021

Roche Basel Switzerland

Roche submits Kadcyla for FDA Real-Time review

Aims to extend use in breast cancer patients

- PMLiVE

Europe closer to biosimilar rule change, despite fierce resistance from pharma

EFPIA says it weakens IP commitment - supporters say it will boost exports

- PMLiVE

Evenity back on track with FDA panel blessing in osteoporosis

US drugs regulator first rejected the drug due to cardiovascular concerns

- PMLiVE

FDA takes aim at pharma’s biosimilar-delaying tactics

Ever-rising cost of insulins also to be targeted

- PMLiVE

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

BiTE will rival therapies from Bluebird, Celgene/Juno, J&J/Legend biotech

- PMLiVE

NHS says Humira biosimilar deal will save £300m

AbbVie also submitted a bid into tender process

- PMLiVE

Amgen CEO says Aimovig is “one of most successful launches”

Contrasts with cholesterol drug Repatha, its price slahed 60% to lift take-up

- PMLiVE

MS and cholesterol drugs picked for new UK rapid uptake push

Accelerated Access Collaborative aims to break down barriers to faster uptake

- PMLiVE

UK ‘unicorn’ Oxford Nanopore bags $65m backing from Amgen

Big biopharma investment good news for gene sequencing company

- PMLiVE

First Humira biosimilars reach EU market

World's biggest selling medicine to lose billions in sales

AstraZeneca AZ

AZ, Amgen’s first-in-class asthma drug gets breakthrough status

Clinical data from the TSLP targeting antibody is due in 2020

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links